TRVI
Trevi Therapeutics, Inc.
OpenVolumeMkt capP/EEPSDiv yield
Day – 52-wk –
Expected move
InputsNext report
Last report
Largest filed tie
13F top-10 QoQ
Top fund weight
Trevi Therapeutics, Inc.
Expected move
InputsNext report
Last report
Largest filed tie
13F top-10 QoQ
Top fund weight
No other changes.
No other changes.
Last report0 of 8 at or beyond impliedshaded = implied▲▼ = realized× = |realized| ÷ implied
Annual filing, covered
10-K parsed · Mar 17 '26
Supply-chain ties, covered
Disclosed · both directions
Fund holders, covered
N-PORT holdings
13F holdings, covered
13F quarter · Jun 30 '26
Management, not covered
Not covered · DEF 14A, 8-K 5.02
Company IR feed, not covered
News via newswires & EDGAR
Products, patents, hiring, not covered
Not covered
Annual filing, covered
10-K parsed · Mar 17 '26
Supply-chain ties, covered
Disclosed · both directions
Fund holders, covered
N-PORT holdings
13F holdings, covered
13F quarter · Jun 30 '26
Management, not covered
Not covered · DEF 14A, 8-K 5.02
Company IR feed, not covered
News via newswires & EDGAR
Products, patents, hiring, not covered
Not covered
No thesis.
Trevi Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of Haduvio to treat serious neurologically mediated conditions. The company is developing Haduvio, an oral extended-release formulation of nalbuphine, which is in phase IIb/III clinical trial for the treatment of chronic pruritus, chronic cough in patients with idiopathic pulmonary fibrosis. It has a license agreement with Endo Pharmaceuticals Inc. to develop and commercialize products incorporating nalbuphine hydrochloride in any formulation. The company was incorporated in 2011 and is headquartered in New Haven, Connecticut.
Trevi Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of Haduvio to treat serious neurologically mediated conditions. The company is developing Haduvio, an oral extended-release formulation of nalbuphine, which is in phase IIb/III clinical trial for the treatment of chronic pruritus, chronic cough in patients with idiopathic pulmonary fibrosis. It has a license agreement with Endo Pharmaceuticals Inc. to develop and commercialize products incorporating nalbuphine hydrochloride in any formulation. The company was incorporated in 2011 and is headquartered in New Haven, Connecticut.
Same SIC code · 6
Same SEC industry code: ELI Lilly & Co, Johnson & Johnson, AbbVie Inc. and 3 more; of Trevi Therapeutics, Inc.'s 6 closest co-movers, none share that code.
Same SIC code · 6
Same SEC industry code: ELI Lilly & Co, Johnson & Johnson, AbbVie Inc. and 3 more; of Trevi Therapeutics, Inc.'s 6 closest co-movers, none share that code.
+0.05%
vs ±14.8% implied · ×0.00
shaded = implied · ▲▼ = realized
Trevi Therapeutics, Inc.
13.77
−0.09 · −0.66%
| Manager | Value | % base | |
|---|---|---|---|
| NEA | $246.6M | 8.79% | 0.00% |
| FMR | $234.3M | 8.35% | +56.29% |
| BlackRockindex-like | $208.0M | 7.42% | +8.93% |
| Frazier Life Sciences | $185.4M | 6.61% | 0.00% |
| Wellington | $106.0M | 3.78% | +9.55% |
| Manager | Value | % base | |
|---|---|---|---|
| NEA | $246.6M | 8.79% | 0.00% |
| FMR | $234.3M | 8.35% | +56.29% |
| BlackRockindex-like | $208.0M | 7.42% | +8.93% |
| Frazier Life Sciences | $185.4M | 6.61% | 0.00% |
| Wellington | $106.0M | 3.78% | +9.55% |
Bull2
Bear2
Tall tick = annual report · Source: EDGAR
Largest filed tie
—
Expected move
Inputsspot 13.86exp Nov 20ATM strike 14ATM straddle 3.30IV 138%